Nonylphenol-induced hyperadrenalism can be reversed/alleviated by inhibiting of 11-β hydroxysteroid dehydrogenase type 1

被引:3
|
作者
Chang, Ling-Ling [1 ]
Wun, Wan-Song A. [2 ]
Wang, Paulus S. [3 ,4 ,5 ,6 ]
机构
[1] Chinese Culture Univ, Dept Chem & Mat Engn, Taipei 11114, Taiwan
[2] Houston Fertil Specialists, Houston, TX 77054 USA
[3] Natl Yang Ming Univ, Sch Med, Dept Physiol, Taipei 11221, Taiwan
[4] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan
[5] China Med Univ Hosp, Med Ctr Aging Res, Taichung 40402, Taiwan
[6] Asia Univ, Dept Biotechnol, Taichung 41354, Taiwan
关键词
NP; PF915275; Adipogenesis; 11; beta-HSD1; Hyperadrenalism; Metabolic syndrome; INSULIN-RESISTANCE; METABOLIC SYNDROME; GLUCOSE-TRANSPORTER; PLASMA ADIPONECTIN; RAT; SECRETION; EXPOSURE; SENSITIVITY; OBESITY; MODEL;
D O I
10.1016/j.etap.2016.03.019
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
We previously observed that nonylphenol (NP) exposure during development resulted in increases in body weight and hyperadrenalism in adult male offspring. The mechanism of hyperadrenalism includes the primary activation of the adrenal gland and the conversion of inactive glucocorticoids to active glucocorticoids by 11 beta-HSD1. The inhibition of 11 beta-HSD1 is investigated as a new therapeutic approach. This study examined the effect of PF915275 (a selective 11 beta-HSD1 inhibitor) on hyperadrenalism and adipogenesis in male rats exposed to NP during development. The results showed that treatment with the 11 beta-HSD1 inhibitor PF915275 reversed/alleviated NP-induced hyperadrenalism via the following mechanisms: (1) decreasing serum corticosterone, 11 beta-hydroxylase, and aldosterone synthase levels; (2) significantly increasing PPAR alpha protein and mRNA expression. In adipose tissue, NP significantly increased PPAR gamma mRNA expression, whereas PF915275 significantly decreased the level of mRNA expression; and (3) the expression of key regulators/enzymes in the adipogenesis metabolic pathway was also modulated. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [21] Calcitriol regulation of 11-β hydroxysteroid dehydrogenase 1 (11-β-HSD1) and angiotensin II receptor 1 (AT1) expression in human adipocytes
    Morris, KL
    Miller, SL
    Zemel, MB
    FASEB JOURNAL, 2004, 18 (05): : A878 - A878
  • [22] The increased ratio of 11β-hydroxysteroid dehydrogenase type 1 versus 11β-hydroxysteroid dehydrogenase type 2 in chronic periodontitis irrespective of obesity
    Nakata, Takaya
    Fujita, Atsuko
    Umeda, Makoto
    Yoshida, Hiroaki
    Inami, Kaoru
    Masuzaki, Hiroaki
    Sawai, Hirofumi
    SPRINGERPLUS, 2016, 5 : 1 - 7
  • [23] 11β-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages
    Thieringer, R
    Le Grand, CB
    Carbin, L
    Cai, TQ
    Wong, BM
    Wright, SD
    Hermanowski-Vosatka, A
    JOURNAL OF IMMUNOLOGY, 2001, 167 (01): : 30 - 35
  • [24] 11β-hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes
    Stulnig, TM
    Waldhäusl, W
    DIABETOLOGIA, 2004, 47 (01) : 1 - 11
  • [25] 11β-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes
    T. M. Stulnig
    W. Waldhäusl
    Diabetologia, 2004, 47 : 1 - 11
  • [26] Microglia Express Functional 11β-Hydroxysteroid Dehydrogenase Type 1
    Gottfried-Blackmore, Andres
    Sierra, Amanda
    Mcewen, Bruce S.
    Ge, Renshan
    Bulloch, Karen
    GLIA, 2010, 58 (10) : 1257 - 1266
  • [27] Piperidine amides as 11β-hydroxysteroid dehydrogenase type 1 inhibitors
    Flyren, Katarina
    Bergquist, Lars O.
    Castro, Victor M.
    Fotsch, Christopher
    Johansson, Lars
    Jean, David J. St., Jr.
    Sutin, Lori
    Williams, Meredith
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (12) : 3421 - 3425
  • [28] 11β-Hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome
    Wake, DJ
    Walker, BR
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 215 (1-2) : 45 - 54
  • [29] Glucocorticoids, 11β-hydroxysteroid dehydrogenase type 1, and visceral obesity
    Paulmyer-Lacroix, O
    Boullu-Ciocca, S
    Oliver, C
    Dutour, A
    Grino, M
    M S-MEDECINE SCIENCES, 2003, 19 (04): : 473 - 476
  • [30] Perhydroquinolylbenzamides as novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1
    Coppola, GM
    Kukkola, PJ
    Stanton, JL
    Neubert, AD
    Marcopulos, N
    Bilci, NA
    Wang, H
    Tomaselli, HC
    Tan, J
    Aicher, TD
    Knorr, DC
    Jeng, AY
    Dardik, B
    Chatelain, RE
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (21) : 6696 - 6712